LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Gesloten

SectorGezondheidszorg

13.24 1.46

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.02

Max

13.33

Belangrijke statistieken

By Trading Economics

Inkomsten

-9.7B

2.2B

Verkoop

-11B

76B

K/W

Sectorgemiddelde

24.556

49.888

Dividendrendement

0.63

Winstmarge

2.928

Werknemers

27,527

EBITDA

-13B

6.1B

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.63%

2.38%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

68M

11B

Vorige openingsprijs

11.78

Vorige sluitingsprijs

13.24

Nieuwssentiment

By Acuity

50%

50%

155 / 344 Rangschikking in Healthcare

Dr Reddy's Laboratories Ltd-ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 okt 2025, 14:47 UTC

Belangrijke Marktbewegers

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

12 mei 2026, 12:16 UTC

Winsten

Dr. Reddy's Co-Chairman: Branded Businesses, Currency Tailwinds Partially Mitigated Impact >500124.BY

12 mei 2026, 12:16 UTC

Winsten

Dr. Reddy's Co-Chairman: FY Performance Reflects Impact of Lower Lenalidomide Sales, Several One-Offs >500124.BY

12 mei 2026, 12:08 UTC

Winsten

Dr. Reddy's Laboratories Board Recommends Final Dividend of INR8/Shr >500124.BY

12 mei 2026, 12:06 UTC

Winsten

Dr. Reddy's Laboratories 4Q EPS INR2.64 >500124.BY

12 mei 2026, 12:02 UTC

Winsten

Dr. Reddy's Laboratories 4Q Net INR2.2B Vs. Net INR15.9B >500124.BY

12 mei 2026, 12:01 UTC

Winsten

Dr. Reddy's Laboratories 4Q Rev INR75.16B Vs. INR85.06B >500124.BY

23 jul 2025, 17:49 UTC

Winsten

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

23 jul 2025, 17:48 UTC

Winsten

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

23 jul 2025, 17:48 UTC

Winsten

Dr Reddy's Labs 1Q Rev $85.45B >RDY

Peer Vergelijking

Prijswijziging

Dr Reddy's Laboratories Ltd-ADR Prognose

Beoordelingsconsensus

By TipRanks

Sell

1 ratings

0

Buy

0

Hold

1

Sell

Sentiment

By Acuity

155 / 344 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
help-icon Live chat